Jasper Therapeutics (JSPR) Interest & Investment Income (2022 - 2025)
Jasper Therapeutics (JSPR) posted quarterly Interest & Investment Income of $338000.0 for Q4 2025, down 63.97% year-over-year from $938000.0 in Q4 2024, and down 1.17% quarter-over-quarter from $342000.0 in Q3 2025.
Jasper Therapeutics (JSPR) Interest & Investment Income (2022 - 2025) Analysis & Trends
Jasper Therapeutics' Interest & Investment Income history runs 4 years deep, the most recent figure standing at $338000.0 for Q4 2025.
- In Q4 2025, Interest & Investment Income fell 63.97% year-over-year to $338000.0; the TTM figure through Dec 2025 stood at $1.7 million (down 65.58% YoY), while the FY2025 annual figure was $1.7 million, down 65.58% from the prior year.
- Interest & Investment Income for Q4 2025 stood at $338000.0, down from $342000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $1.4 million in Q2 2024, with the low at $2000.0 in Q1 2022.
- The 4-year median for Interest & Investment Income is $781000.0 (2024), against an average of $793687.5.
- The sharpest annual moves came in 2023 and 2025: Interest & Investment Income soared 54700.0% in 2023, then slumped 73.36% in 2025.
- Jasper Therapeutics' Interest & Investment Income stood at $348000.0 in 2022, then soared by 254.6% to $1.2 million in 2023, then fell by 23.99% to $938000.0 in 2024, then sank by 63.97% to $338000.0 in 2025.
- Business Quant data shows JSPR's Interest & Investment Income at $338000.0 in Q4 2025, $342000.0 in Q3 2025, and $437000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Jasper Therapeutics | 20.08 Mn | 20.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 338,000.00 |
| Sep 30, 2025 | 342,000.00 |
| Jun 30, 2025 | 437,000.00 |
| Mar 31, 2025 | 624,000.00 |
| Dec 31, 2024 | 938,000.00 |
| Sep 30, 2024 | 1.28 Mn |
| Jun 30, 2024 | 1.45 Mn |
| Mar 31, 2024 | 1.39 Mn |
| Dec 31, 2023 | 1.23 Mn |
| Sep 30, 2023 | 1.43 Mn |
| Jun 30, 2023 | 1.44 Mn |
| Mar 31, 2023 | 1.10 Mn |
| Dec 31, 2022 | 348,000.00 |
| Sep 30, 2022 | 259,000.00 |
| Jun 30, 2022 | 92,000.00 |
| Mar 31, 2022 | 2,000.00 |